Wolfe Research analyst Nigel Coe downgrades Regal Rexnord (NYSE:RRX) from Outperform to Peer Perform.
Impel Pharmaceuticals Announces Exploration Of Strategic Alternatives
Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet
